Medicenna Therapeutics Corp. (MDNAF)
Market Open
19 Dec, 15:25
NASDAQ NASDAQ Primary $
0. 75
-0.04
-4.6%
$
10.93M Market Cap
- P/E Ratio
0% Div Yield
75,100 Volume
- Eps
$ 0.78
Previous Close Day Range
0.75 0.77
Year Range
0.57 1.43
Want to track MDNAF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 55 days
Summary
MDNAF trading today lower at $0.75, a decrease of 4.6% from yesterday's close, completing a monthly decrease of -32.79% or $0.36. Over the past 12 months, MDNAF stock lost -34.56%.
MDNAF is not paying dividends to its shareholders.
The last earnings report, released on Nov 14, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.02%, based on the last three reports. The next scheduled earnings report is due on Feb 12, 2026.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (USD).
MDNAF Chart
Similar
Medicenna Therapeutics (MDNAF) Upgraded to Buy: Here's What You Should Know
Medicenna Therapeutics (MDNAF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks | 2 months ago
Medicenna Therapeutics Corp. (MDNAF) FAQ
What is the stock price today?
The current price is $0.75.
On which exchange is it traded?
Medicenna Therapeutics Corp. is listed on NASDAQ.
What is its stock symbol?
The ticker symbol is MDNAF.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0%.
What is its market cap?
As of today, the market cap is 10.93M.
When is the next earnings date?
The next earnings report will release on Feb 12, 2026.
Has Medicenna Therapeutics Corp. ever had a stock split?
No, there has never been a stock split.
Medicenna Therapeutics Corp. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Fahar Merchant Ph.D. CEO | NASDAQ Exchange | CA58490H1073 ISIN |
| Canada Country | 16 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Medicenna Therapeutics Corp. is an immunotherapy company with a focus on the research, development, and commercialization of novel and innovative treatments for cancer and other serious diseases. Based in Toronto, Canada, the company leverages its expertise in the field of immunotherapy to create Superkines and empowered Superkines, which are designed to manipulate the body's immune system to target and destroy cancer cells more effectively. Medicenna's commitment to advancing cancer treatment options highlights its role at the forefront of medical research in immunotherapy.
Products and Services
- MDNA55: This product is an interleukin-4 (IL-4) Empowered Cytokine (EC) specifically engineered for the treatment of recurrent glioblastoma, a highly aggressive form of brain tumor. MDNA55 targets tumor cells by leveraging the IL-4 receptor's pathway, aiming to offer a targeted approach to cancer treatment.
- MDNA11: An enhanced version of IL-2, MDNA11 is designed to activate and proliferate the immune system's cells that are crucial for fighting cancer. By improving on the properties of traditional IL-2, MDNA11 seeks to boost the body's natural defenses against cancer with fewer side effects.
- MDNA209: Focused on treating autoimmune diseases such as multiple sclerosis and graft-versus-host disease, MDNA209 is an IL-2 antagonist. It aims to modulate the immune system to prevent it from attacking the body's own tissues, offering a potential treatment for various autoimmune conditions.
- MDNA413: A dual IL-4/IL-13 antagonist, MDNA413 is being developed for use in cancer immunotherapies. By blocking the action of both interleukin-4 and interleukin-13, it is aimed at overcoming the immune system's suppression within the tumor microenvironment, enhancing the efficacy of cancer treatments.
- MDNA132: This IL-13 Superkine is targeted at treating solid tumors. By precisely targeting and binding to IL-13 receptors, which are often overexpressed in many types of solid tumors, MDNA132 intends to offer a novel approach to stopping tumor growth and spreading.
- BiSKITs Platform: Medicenna’s BiSKITs (Bi-specific SuperKine ImmunoTherapeutics) platform is an innovative technology designed to develop designer Superkines. By fusing Superkines to other proteins, antibodies, cytokines, or even other Superkines, the platform aims to generate new, more effective immunotherapies.
Contact Information
Address: 2 Bloor Street West
Phone: 416- 648-5555
Website: https://www.medicenna.com
